MSLE
No price yet
Announcements
Nothing here yet
Daily updates
- Satellos Bioscience is evaluating forazapadin (SAT-3247) in the BASECAMP Phase 2 trial in healthy volunteers and patients with Duchenne muscular dystrophy, with topline data expected in Q1 2027. The study is assessing safety, tolerability, and clinical activity, with the data intended to support future regulatory discussions on an accelerated development pathway.Oct 4, 2026
- Satellos Bioscience received FDA clearance for its IND application for forazapadin in facioscapulohumeral muscular dystrophy, enabling plans to initiate a Phase 2 proof-of-concept study in Q4 2026.Sep 24, 2026
FDA designations
Nothing here yet
News
- Satellos announces completion of enrollment in the Phase 2 BASECAMP trial of forazapadin for Duchenne muscular dystrophySep 30, 2026
- Satellos receives FDA clearance of the IND application for forazapadin in facioscapulohumeral muscular dystrophy and partners with FSHD Canada Foundation for non-dilutive clinical development fundingSep 24, 2026
- Satellos reported positive six-month interim TRAILHEAD data for SAT-3247 in adults with Duchenne muscular dystrophyJul 8, 2026